Overexpression of wild-type THRβ1 suppresses the growth and invasiveness of human papillary thyroid cancer cells

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3999-4009

  Sedliarou, Ilya ^a   Matsuse, Michiko ^a   Saenko, Vladimir ^a   Rogounovitch, Tatiana ^a   Nakazawa, Yuka ^a   Mitsutake, Norisato ^a   Namba, Hiroyuki ^a   Nagayama, Yuji ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Cell cycle; Cell growth; Invasiveness; Papillary thyroid carcinoma; Thyroid hormone receptor beta

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR BETA 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER;

ADENOVIRIDAE; CARCINOMA, PAPILLARY; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 37549047941     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. DeLellis RA, Lloyd RV, Heitz PU and Eng C: Pathology and Genetics of Tumors of Endocrine Organs. Lyon, IARC Press, p. 320, 2004.
2. Mazzaferri EL and Jhiang SM: Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 106: 151-168, 1994.
3. Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428, 1994.
4. DeGroot LJ, Mangklabruks A and McCormick M: Comparison of RA 1311 treatment protocols for Graves' disease. J Endocrinol Invest 75: 111-118, 1990.
5. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19: 545-576, 1990.
6. Fagin JA: Perspective: lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143: 2025-2028, 2002.
7. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R and Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580, 2003.
8. Namba H, Rubin SA and Fagin JA: Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474-1479, 1990.
9. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397, 2003.
10. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003.
11. Marshall CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4: 82-89, 1994.
12. Marais R and Marshall CJ: Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 27: 101-125, 1996.
13. Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, Larsen CJ and Karayan-Tapon L: Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol 32: 228-230, 2006.
14. Boltze C, Hoang-Vu C, Schneider-Stock R, Lehnert H and Roessner A: Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis. Verh Dtsch Ges Pathol 88: 237-245, 2004.
15. Boltze C, Zack S, Quednow C, Bettge S, Roessner A and Schneider-Stock R: Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract 199: 399-404, 2003.
16. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M and Wynford-Thomas D: High frequency deletion of the tumor suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol 116: 115-119, 1996.
17. Chen Y, Zhang P, Li Y, Zhuang J and Gao L: Clinicopathologic significance of structural alterations of p53 protein in papillary thyroid carcinoma. Zhonghua Bing Li Xue Za Zhi (in Chinese) 31: 217-221, 2002.
18. Lin KH, Shieh HY, Chen SL and Hsu HC: Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26: 53-61, 1999.
19. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY and Nauman A: Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23: 25-33, 2002.
20. Gonzalez-Sancho JM, Garcia V, Bonilla F and Munoz A: Thyroid hormone receptors/THR genes in human cancer. Cancer Lett 192: 121-132, 2003.
21. Markowitz S, Haut M, Stellato T, Gerbic C and Molkentin K: Expression of the ErbA-beta class of thyroid hormone receptors is selectively lost in human colon carcinoma. J Clin Invest 84: 1683-1687, 1989.
22. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY and Nauman J: Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87: 1120-1128, 2002.
23. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY and Ringel MD: AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146: 4456-4463, 2005.
24. Kawabe Y, Eguchi K, Shimomura C, Mine M, Otsubo T, Ueki Y, Tezuka H, Nakao H, Kawakami A and Migita K: Interleukin-1 production and action in thyroid tissue. J Clin Endocrinol Metab 68: 1174-1183, 1989.
25. Samuels HH, Stanley F and Casanova J: Depletion of L-3,5,3′- triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology 105: 80-85, 1979.
26. Melmed S and Yamashita S: Insulin-like growth factor-I action on hypothyroid rat pituitary cells: suppression of triiodothyronine-induced growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118: 1483-1490, 1986.
27. Beck-Peccoz P, Chatterjee VK, Chin WW, DeGroot LJ, Jameson JL, Nakamura H, Refetoff S, Usala SJ and Weintraub BD: Nomenclature of thyroid hormone receptor-beta gene mutations in resistance to thyroid hormone: consensus statement from the First Workshop on Thyroid Hormone Resistance. Eur J Endocrinol 130: 426-428, 1994.
28. Mizuguchi H and Kay MA: A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 12: 2013-2017, 1999.
29. Nagayama Y, Nishihara E, Namba H, Yokoi H, Hasegawa M, Mizuguchi H, Hayakawa T, Hamada H, Yamashita S and Niwa M: Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system. Cancer Gene Ther 8: 36-44, 2001.
30. Mittereder N, March KL and Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498-7509, 1996.
31. Karakashian AA, Giltiay NV, Smith GM and Nikolova-Karakashian MN: Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation. FASEB J 18: 968-970, 2004.
32. Hwang ES and Lee HJ: Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood) 231: 322-327, 2006.
33. Takano T, Miyauchi A, Yoshida H, Nakata Y, Kuma K and Amino N: Expression of TRbetal mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma. J Clin Endocrinol Metab 88: 3447-3449, 2003.
34. Rocha AS, Marques R, Bento I, Soares R, Magalhaes J, de Castro IV and Soares P: Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas. J Endocrinol 192: 83-86, 2007.
35. Treuter E, Johansson L, Thomsen JS, Warnmark A, Leers J, Pelto-Huikko M, Sjoberg M, Wright AP, Spyrou G and Gustafsson JA: Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. Implications for the recruitment of TRAP and p160 coactivator complexes. J Biol Chem 274: 6667-6677, 1999.
36. Zhang J and Fondell JD: Identification of mouse TRAP100: a transcriptional coregulatory factor for thyroid hormone and vitamin D receptors. Mol Endocrinol 13: 1130-1140, 1999.
37. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, Iwama T and Miyaki M: p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12: 1565-1569, 1996.
38. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH and Peters DJ: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348-351, 1995.
39. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T and Kakudo K: Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathol Int 56: 240-245, 2006.
40. Garcia-Silva S and Aranda A: The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol 24: 7514-7523, 2004.
41. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
42. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
43. Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, Nishiyama K, Nagayama K, Misawa H, Masuda H and Nakamura H: Beta-catenin/Tcf-1- mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun 309: 408-413, 2003.
44. Forough R, Weylie B, Collins C, Parker JL, Zhu J, Barhoumi R and Watson DK: Transcription factor Ets-1 regulates fibroblast growth factor-1-mediated angiogenesis in vivo: role of Ets-1 in the regulation of the PI3K/AKT/MMP-1 pathway. J Vasc Res 43: 327-337, 2006.
45. Kunapuli P, Kasyapa CS, Hawthorn L and Cowell JK: LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem 279: 23151-23157, 2004.
46. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
47. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F and Elisei R: Correlation between B-RAF V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13: 455-464, 2006.